Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24173193 | 1.00 | KMT2A (0.31) | KMT2AATMMCL1CA12CA2 | |
| SCHEMBL20314988 | 0.86 | CA12 (0.35) | KMT2AATMMCL1CA12CA2 | |
| SCHEMBL22880758 | 0.83 | MCL1 (0.40) | KMT2AATMMCL1 | |
| SCHEMBL15865786 | 0.81 | CA12 (0.39) | MCL1CA12CA2CA9 | |
| SCHEMBL16264304 | 0.77 | ALDH1A1 (0.37) | KMT2AMCL1CA12CA2CA9 | |
| SCHEMBL20755966 | 0.72 | CA1 (0.34) | KMT2AATMMCL1CA12CA2 | |
| SCHEMBL21610110 | 0.71 | MCL1 (0.32) | MCL1CA12CA2CA9 | |
| SCHEMBL27000303 | 0.71 | FDPS (0.36) | KMT2AMCL1CA12CA2CA9 | |
| SCHEMBL20314982 | 0.71 | CA12 (0.38) | KMT2AATMMCL1CA12CA2 | |
| SCHEMBL20327119 | 0.70 | MCL1 (0.33) | KMT2AATMMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053226-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200165231-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053226-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | KMT2A 2069/4885ATM 2171/4885MCL1 159/4885 |
| US-20200165231-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KMT2A 2069/4885ATM 2171/4885MCL1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.